Evidence map›Paper›PMID 31266172›Full record

Trial reportToxins2019

Botulinum Toxin Type A and Physiotherapy in Spasticity of the Lower Limbs Due to Amyotrophic Lateral Sclerosis.

Riccardo Marvulli, Marisa Megna, Aurora Citraro, Ester Vacca, Marina Napolitano, Giulia Gallo, Pietro Fiore, Giancarlo Ianieri

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in Toxins, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Progressive Bulbar Palsy (PBP) or Bulbar Onset MND: "A Case Report".Journal of pharmacy & bioallied sciences · 2025
    Article
  5. Review
  6. Primary Lateral Sclerosis: An Overview.Journal of clinical medicine · 2024
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Riccardo MarvulliDepartment of Basic Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", G. Cesare Place 11, 70125 Bari, Italy. ricmarv81@hotmail.it.ORCID 0000-0002-3617-7452
Marisa MegnaDepartment of Basic Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", G. Cesare Place 11, 70125 Bari, Italy.
Aurora CitraroDepartment of Basic Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", G. Cesare Place 11, 70125 Bari, Italy.
Ester VaccaDepartment of Basic Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", G. Cesare Place 11, 70125 Bari, Italy.
Marina NapolitanoDepartment of Basic Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", G. Cesare Place 11, 70125 Bari, Italy.
Giulia GalloDepartment of Basic Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", G. Cesare Place 11, 70125 Bari, Italy.
Pietro FioreDepartment of Basic Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", G. Cesare Place 11, 70125 Bari, Italy.
Giancarlo IanieriDepartment of Basic Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", G. Cesare Place 11, 70125 Bari, Italy.
University of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease (unknown pathogenesis) of the central nervous system that causes death within 1-5 years. Clinically, flabby paralysis, areflexia, muscular atrophy, and muscle fasciculations, signs of II motor neuron damage, appear. Sometimes, clinical manifestations of damage of the I motor neuron come out in lower limbs; spastic paralysis, iperflexia, and clonus emerge, and they impair deambulation and management of activities of daily living, such as personal hygiene or dressing. Thus, the first therapeutic approach in these patients involves antispasmodic drugs orally followed by botulinum toxin type A injection (BTX-A). In this study, we study the efficacy of BTX-A and physiotherapy in lower limb spasticity due to ALS and no response to treatment with oral antispastic drugs. We evaluated 15 patients (10 male and five female), with a mean age of 48.06 ± 5.2 with spasticity of adductor magnus (AM), at baseline (T0, before BTX-A treatment) and in the following three follow-up visits (T1 30 days, T2 60 days, and T3 90 days after infiltration). We evaluated myometric measure of muscle tone, the Modified Ashworth Scale of AM, Barthel Index, Adductor Tone Rating Scale, and Hygiene Score. The study was conducted between November 2018 and April 2019. We treated AM with incobotulinum toxin type A (Xeomin

Indexed as

Physical Therapy ModalitiesAdultAmyotrophic Lateral SclerosisBotulinum Toxins, Type AFemaleHumansLower ExtremityMaleMiddle AgedMuscle SpasticityNeuromuscular AgentsTreatment OutcomeBotulinum Toxins, Type AincobotulinumtoxinANeuromuscular Agentsactivities of daily livingamyotrophic lateral sclerosisbotulinum toxin type Alower limb spasticityphysiotherapy

Identifiers

PMID31266172
PMCPMC6669765
OpenAlexW2954694270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.